Key facts
- Notable investors include Hangzhou Huadian Investment Management, HiMed Fund, Penglai Capital, Tenedge Investment, Tofflon Science and Technology Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Biosmelt Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosmelt Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosmelt Pharma
Provider of preclinical CRO services for cell and gene therapy, novel antibodies, nucleic acid drugs, and exosomes. The company offers a range of services such as early stage pilot process development, process verification, quality analysis, and registration application to biopharmaceutical companies.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- biosmelt.com/
- Ownership
- Privately Held (backing)
Biosmelt Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosmelt Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosmelt Pharma in its N-PORT filings yet. We sweep new filings monthly.